Atul (500027) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
24 Apr, 2026Executive summary
Audited standalone and consolidated financial results for the year ended March 31, 2026, were approved with unmodified audit opinions from the statutory auditors.
Board recommended a dividend of ₹30 per equity share, subject to shareholder approval at the AGM on July 31, 2026.
Mr. Samveg Lalbhai was reappointed as Managing Director for five years, effective December 15, 2026, pending member approval.
Financial highlights
Standalone revenue from operations for FY26 was ₹5,563.57 crore, up from ₹5,074.69 crore in FY25.
Standalone net profit after tax for FY26 was ₹595.04 crore, compared to ₹456.28 crore in FY25.
Consolidated revenue from operations for FY26 was ₹6,273.54 crore, up from ₹5,583.35 crore in FY25.
Consolidated net profit after tax for FY26 was ₹689.39 crore, compared to ₹498.83 crore in FY25.
Basic and diluted EPS (consolidated) for FY26 was ₹230.25, up from ₹164.37 in FY25.
Outlook and guidance
Dividend of ₹30 per share (300%) recommended, subject to shareholder approval.
Company continues to monitor regulatory changes, especially regarding new labour codes, and will adjust estimates as needed.
Latest events from Atul
- Q1 FY27 saw double-digit revenue and profit growth, with strong segment performance and board expansion.500027
Q1 26/27 - Q3 FY26 consolidated net profit rose to ₹163.54 crore on revenue of ₹1,573.62 crore.500027
Q3 25/26 - Strong revenue and profit growth in H1 FY2025, led by core chemical segments.500027
Q2 25/26 - Strong revenue and profit growth driven by robust segment performance and clean audit review.500027
Q1 24/25 - Q2 FY25 saw strong revenue and profit growth, led by chemicals segments and robust margins.500027
Q2 24/25 - Q3 FY25 saw higher revenue and profit year-over-year, with robust segment performance.500027
Q3 24/25 - Revenue and profit rose, dividend of ₹25/share proposed, and new Secretarial Auditors appointed.500027
Q4 24/25 - Consolidated revenue and profit rose year-over-year, led by strong chemical segment growth.500027
Q1 25/26